154 related articles for article (PubMed ID: 19016745)
21. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
22. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
23. Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13).
Nakamura Y; Nakazato H; Sato Y; Furusawa S; Mitani K
Am J Hematol; 2002 Jan; 69(1):80-2. PubMed ID: 11835339
[TBL] [Abstract][Full Text] [Related]
24. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
25. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
[TBL] [Abstract][Full Text] [Related]
26. A 5' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model.
Nagamachi A; Htun PW; Ma F; Miyazaki K; Yamasaki N; Kanno M; Inaba T; Honda Z; Okuda T; Oda H; Tsuji K; Honda H
Dev Biol; 2010 Sep; 345(2):226-36. PubMed ID: 20647008
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
28. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
29. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia.
Pekarsky Y; Rynditch A; Wieser R; Fonatsch C; Gardiner K
Cancer Res; 1997 Sep; 57(18):3914-9. PubMed ID: 9307271
[TBL] [Abstract][Full Text] [Related]
30. Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.
Matsuura S; Yan M; Lo MC; Ahn EY; Weng S; Dangoor D; Matin M; Higashi T; Feng GS; Zhang DE
Blood; 2012 Mar; 119(13):3155-63. PubMed ID: 22223820
[TBL] [Abstract][Full Text] [Related]
31. Leukemogenesis by CBF oncoproteins.
Friedman AD
Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
[TBL] [Abstract][Full Text] [Related]
32. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
[TBL] [Abstract][Full Text] [Related]
33. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
Nucifora G; Rowley JD
Blood; 1995 Jul; 86(1):1-14. PubMed ID: 7795214
[No Abstract] [Full Text] [Related]
34. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene.
Asou H; Suzukawa K; Kita K; Nakase K; Ueda H; Morishita K; Kamada N
Jpn J Cancer Res; 1996 Mar; 87(3):269-74. PubMed ID: 8613429
[TBL] [Abstract][Full Text] [Related]
35. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
[TBL] [Abstract][Full Text] [Related]
36. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.
Shen L; Zhu J; Chen F; Lin W; Cai J; Zhong J; Zhong H
BMC Cancer; 2015 Dec; 15():970. PubMed ID: 26674644
[TBL] [Abstract][Full Text] [Related]
37. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
[TBL] [Abstract][Full Text] [Related]
38. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
39. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
40. RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
Kellaway SG; Keane P; Kennett E; Bonifer C
Haematologica; 2021 Jun; 106(6):1569-1580. PubMed ID: 32299907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
